
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo is attractive because its Q2 revenue of $11.7 million rose 21% year over year and exceeded both estimates and guidance, while EPS of $(0.09) also beat expectations, signaling better operating leverage than the market likely anticipated. The company’s unit sales, reimbursement pipeline of 1,491, and insurance-authorized backlog of 218 show durable demand, and raised 2026 revenue guidance to $45–47 million reflects management’s confidence in continued execution. Fundamentally, the March 2024 CMS ruling expands Medicare Part B access for MyoPro, accelerating U.S. O&P growth and supporting a large addressable market, with international revenue already up 32% year over year in Q2.
Bears say
Myomo is exposed to significant fundamental risk because its business depends on balance sheet and liquidity strength, yet it must continue funding commercialization, clinical validation, and regulatory maintenance for a specialized medical device. Its MyoPro platform also faces reimbursement uncertainty, as revenues rely on insurance billing and acceptance by providers and government customers, while competition and changing macroeconomic conditions can pressure adoption and margins. More broadly, investor sentiment toward biotech and medtech remains fragile, and any shift in healthcare priorities or failure to maintain regulatory approvals could materially impair growth and operating stability.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Myomo (MYO) Forecast
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares